Brevan Howard Capital Management’s Gossamer Bio GOSS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-127,299
Closed -$395K 2269
2025
Q4
$395K Buy
127,299
+113,206
+803% +$323K ﹤0.01% 1221
2025
Q3
$37.1K Buy
+14,093
New +$31.1K ﹤0.01% 1899
2025
Q2
Sell
-23,672
Closed -$26K 1904
2025
Q1
$26K Buy
+23,672
New +$27.4K ﹤0.01% 1109
2024
Q2
Sell
-21,377
Closed -$25.2K 1181
2024
Q1
$25.2K Buy
+21,377
New +$23.5K ﹤0.01% 956

Other funds holding GOSS

Brevan Howard Capital Management's GOSS Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 127,299 shares — an estimated $395K sold.

Brevan Howard Capital Management first reported a position in GOSS in Q1 2024 and held it in 4 quarters. The position peaked at $395K in Q4 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 127,299 Gossamer Bio shares in Q1 2026, an estimated $395K.
  • Brevan Howard Capital Management first reported a position in Gossamer Bio in Q1 2024 and held it in 4 quarters.
  • Brevan Howard Capital Management's Gossamer Bio position peaked at $395K in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.